MICRO- OR NANOPARTICULAR MULTILAMELLAR VESICLES, COMPOSITIONS COMPRISING THE SAME AND METHOD FOR THEIR USE IN SKIN CARE

• US 20190314649A1
• Filed: 06/26/2019
• Published: 10/17/2019
• Est. Priority Date: 12/29/2016
• Status: Abandoned Application

• Current Assignee: Galderma Holding SA
• Original Assignee: Nestlé Skin Health S.A (Nestle SA)
• Inventors: MALLARD, Claire, RIVAL, Yves, ANTHONIOZ, Lise
• Application Number:
  US16/453,798
• Publication Number:
  US 20190314649A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 8/14 Liposomes; Vesicles
• CPC Class Codes: A61K 8/4973 with oxygen as the only hetero atom
• CPC Class Codes: A61K 8/735 Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

A micro- or nanoparticular multilamellar vesicle is constituted of concentric membranes comprising at least one non-ionic surfactant of the sucrose ester type comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated C12 to C22 fatty acid, which vesicle comprises at least a hyaluronic acid (HA), wherein the hyaluronic acid is a crosslinked hyaluronic acid. Also disclosed are a method of manufacture of such vesicle, compositions comprising such vesicle and their uses.

Claims

1. A micro- or nanoparticular multilamellar vesicle comprising concentric membranes, comprising:

(a) at least one non-ionic surfactant of the sucrose ester type, comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated, C12 to C22 fatty acid; and

(b) at least a hyaluronic acid, wherein the hyaluronic acid is a crosslinked hyaluronic acid.

2. The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the degree of modification of the crosslinked hyaluronic acid with a chemical crosslinking agent is less than 15 mole %.

3. The micro- or nanoparticular multilamellar vesicle according to claim 2, wherein the degree of modification of the crosslinked hyaluronic acid with the chemical crosslinking agent is less than 1.9 mole %.

4. The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the degree of modification of the crosslinked hyaluronic acid with a chemical crosslinking agent is between 0.1 and 1.9 mole %.

5. The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the crosslinked hyaluronic acid is sodium hyaluronate crosspolymer-2.

6. The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the crosslinked hyaluronic acid is loaded onto the vesicle, into the vesicle, or both.

7. The micro- or nanoparticular multilamellar vesicle according to claim 6, wherein the crosslinked hyaluronic acid is loaded onto the vesicle and/or into the vesicle at a concentration of between 0.01% and 5% (w/w).

8. The micro- or nanoparticular multilamellar vesicle according to claim 7, wherein the crosslinked hyaluronic acid is loaded onto the vesicle and/or into the vesicle at a concentration of 0.175%, 0.35%, or 0.5% (w/w).

9. The micro- or nanoparticular multilamellar vesicle according to claim 6, wherein the crosslinked hyaluronic acid is loaded onto the vesicle.

10. The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the chemical crosslinking agent is a bi- or polyfunctional crosslinking agent comprising two or more glycidyl ether functional groups.

11. The micro-or nanoparticular vesicle according to claim 1, further comprising a non-crosslinked hyaluronic acid, wherein up to 50% by weight of the total hyaluronic acid in the vesicle is non-crosslinked.

14. A composition comprising a micro- or nanoparticular multilamellar vesicle according to claim 1, in a physiologically acceptable medium.

15. The composition according to claim 14, comprising a concentration of the vesicle between 0.1% and 10% by weight, relative to the total weight of the composition.

16. The composition according to claim 15, wherein the concentration of the vesicle is about 1%, about 2%, or about 3% by weight, relative to the total weight of the composition.

17. The composition according to claim 14, wherein the vesicles are cationic vesicles, non-ionic vesicles, or a combination thereof.

18. The composition according to claim 14, wherein the composition is formulated for topical or parenteral application.

19. A method of caring for human skin or reducing the effects of skin ageing, comprising topically applying a composition according to claim 14 to the skin of a human subject in need thereof.

12. A method of manufacturing a micro- or nanoparticular multilamellar vesicle, comprising:

(a) preparing a non-ionic surfactant phase comprising at least one non-ionic surfactant of the sucrose ester type, comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated, C12 to C22 fatty acid;

(b) preparing an aqueous phase comprising at least a hyaluronic acid, wherein the hyaluronic acid is a crosslinked hyaluronic acid;

(c) mixing the aqueous phase into the non-ionic surfactant phase with controlled stirring and heating, to form a preparation containing the multilamellar vesicle comprising surfactant bi-layers; and

(d) diluting the preparation containing the multilamellar vesicle with water.

13. The method according to claim 12, wherein the crosslinked hyaluronic acid is loaded onto the vesicles.